BRASILIA (Reuters) - Brazil’s health regulator Anvisa said on Wednesday it has authorized the import of raw materials from Chinese company Sinovac for the production of its COVID-19 vaccine.
Sao Paulo’s biomedical institute Butantan plans to produce the vaccine.
Reporting by Ricardo Brito, writing by Stephen Eisenhammer, editing by Chris Reese
Our Standards: The Thomson Reuters Trust Principles.